combined blockade of vegf and pd-1 signaling in rcc
Published 5 years ago • 64 plays • Length 1:45Download video MP4
Download video MP3
Similar videos
-
0:57
combined inhibition of parp and vegf in gastric cancer
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
2:30
combining vegf tkis with immunotherapy for rcc
-
1:37
dr. hammers discusses combining ido and pd-1 inhibitors in rcc
-
1:31
combining immunotherapy with vegf inhibitors to treat kidney cancer
-
6:08
pd-1, pd-l1 role in immune system inhibition
-
1:12:27
dissecting the tumor microenvironment in pd1 responsiveness vs. non-responsiveness
-
59:55
kcrs24 session two - novel imaging and biomarkers in rcc patient management
-
1:02
current status of vegf inhibitor/immunotherapy combinations in rcc
-
1:23
pd-1/vegfr blockade for liver cancer
-
1:49
dr. choueiri on subsequent combo therapy after pd-1/pd-l1 blockade in rcc
-
1:52
efficacy of targeted therapies after pd-1/pd-l1 blockade in metastatic renal cell carcinoma
-
5:01
combined targeting against vegf and pd-1 in bladder cancer
-
5:17
vegf and pd-1 inhibition in advanced gastric/gej cancer
-
1:28
dr. sznol on factors to consider when combining vegf tkis/immunotherapy in rcc
-
1:37
dr. choueiri on synergy between immunotherapy and vegf inhibitors in rcc
-
2:31
recent immunotherapy advances in rcc
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
5:53
combining checkpoint inhibitors and vegf inhibitors for first-line rcc: early data and indications
-
1:28:18
navigating evolving standards of care in rcc: novel targeted and immunotherapy options
-
38:09
understanding and working with new immunotherapeutic and targeted management models in advanced rcc
-
1:37
dr. hammers on combinations of ido and pd-1 inhibitors in rcc